Canatu (CANATU) investor relations material

Strategic Vision and Business Model Evolution

• Transitioning from technology validation to scalable value creation, leveraging a unique carbon nanotube (CNT) platform for industry-transforming products in semiconductors, automotive, and medical diagnostics.

• Focused execution and disciplined capital allocation prioritize high-value, scalable applications, with a stage-gate approach for new business development and deprioritization of non-scalable opportunities.

• Employs two business models: reactor/licensing for high-integration, high-volume applications, and direct product sales for high-value, lower-volume domains, emphasizing scalable, asset-light operations.

• Maintains a strong competitive edge through proprietary Dry Deposition™ technology, deep customer integration, and a robust IP portfolio of over 300 patents.

• Addressable market estimated at €3 billion by 2030, with semiconductors as the largest segment.

Financial Targets and Growth Outlook

• Revenue target for 2030 is €100–150 million with an EBIT margin of 25–30%, adjusted for goodwill amortization.

• Semiconductor is the primary growth driver, expected to deliver the highest gross margins and recurring revenue streams by 2030.

• Medical diagnostics and new business development are projected to have the highest relative growth rates, albeit from a smaller base.

• CapEx will peak in 2026 due to facility investments (up to €14–18M), then stabilize at €5–6 million annually.

• Headcount growth of 10–35 FTEs per year is anticipated to support scaling and innovation.

Semiconductor Business Developments

• CNT pellicle technology is moving from validation to scaling, with adoption driven by AI-fueled demand for advanced chips and EUV lithography, targeting 10–20 installed reactors and at least 50% market share in EUV pellicles by 2030.

• Recurring revenues from royalties, consumables, and services are expected to surpass reactor sales by 2030.

• Investments in a new modular semiconductor facility will support capacity expansion and technology leadership.

• Market size estimates for EUV pellicles refined to €800 million by 2030, with key milestones including reactor deliveries, customer approvals, and commercial production licenses.

• CNT pellicles expected to become dominant at 2.0nm and 1.4nm nodes between 2026–2029.